11/4/2023 Rating announcement EN
Scope affirms Sanofi’s AA/Stable issuer rating
The affirmation reflects Sanofi’s resilient operating performance and low indebtedness.
20/4/2022 Rating announcement EN
Scope affirms Sanofi’s AA issuer rating and revises the Outlook to Stable from Positive.
The rating action reflects our view of delayed deleveraging against our previous expectations.
19/5/2021 Rating announcement EN
Scope Ratings affirms Sanofi's AA issuer rating and changes the Outlook to Positive
The ratings continue to reflect Sanofi's improved positioning in growth sectors like rare diseases and immunology as well as management's credit-supportive financial policy.
9/9/2020 Rating announcement EN
Scope affirms AA/Stable issuer rating on Sanofi
The ratings reflect the company's leading position in a number of therapeutic areas as well as recent success with newly approved drugs contributing to a good credit metrics recovery in 2019, which Scope expects to continue.
19/9/2019 Rating announcement EN
Scope affirms Sanofi at AA, Stable Outlook
The rating reflects Sanofi's leading positions in vaccines, anti-diabetics and rare diseases within a credit-supportive underlying industry as well as the strong recovery for credit metrics expected by rating agency.
18/9/2018 Rating announcement EN
Scope affirms AA Sanofi rating
The rating reflects our view of Sanofi's credit metrics' recovery to levels commensurate with the ratings following their temporary deterioration following the acquisitions of Bioverativ and Ablynx in the first half of 2018.
7/9/2017 Rating announcement EN
French pharma Sanofi rated AA and S-1+ by Scope Ratings, Stable Outlook
Scope’s first ratings for Sanofi S.A. are driven by the French group’s credit-supportive industry risk, strong competitive position and sustained track record of good credit metrics. Senior unsecured debt is rated AA.